Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease.

ABSTRACT:

Background and aims

Biosimilar approval, such as Inflectra™ (CT-P13) for treating ulcerative colitis (UC) and Crohn's disease (CD), has reduced direct drug costs. Though clinicians are comfortable with biosimilar use in treatment-naïve patients, there are concerns in some jurisdictions that there are insufficient data from well-controlled trials to support non-medical switching. A systematic review, along with a critical assessment of the study design, was conducted to assess the potential impact of switching stable CD/UC patients from infliximab to CT-P13.

Methods

A literature search using PubMed and abstracts/posters from 3 major gastroenterology conferences from 2014 to 2018 was completed. Two individual reviewers extracted data from each relevant report and compiled it i

SUBMITTER: Bernard EJ 

PROVIDER: S-EPMC7369127 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature